China’s National Medical Products Administration (NMPA) is seeking public comments on new regulations it is drafting on drug registration, drug distribution, and manufacturing. The new regulations, updated in October by the Ministry of Justice, reflect changes made to the Drug Administration Law... Read More
China’s ambitious campaign to expand healthcare coverage and access to innovative drugs is making its pharmaceutical market an increasingly key source of growth for foreign firms. But even as the more than $135 billion pharmaceutical markets in the Asian giant surpasses that... Read More
Spending on cancer drugs is dominating health spending in China, with hospitals in 2018 purchasing more cancer and immunomodulatory drugs than anti-infective drugs for the first time ever. According to data from the China Pharmaceutical Association (CPA), anti-tumor and immunomodulatory treatments represented... Read More
This article was originally published on Medtech Intelligence. Precision medicine, an emerging toolkit of ways to better understand the complex mechanisms underlying a patient’s health, disease, or condition, and to better predict which treatments will be most effective, has grown unevenly outside... Read More
Moving to make it easier for innovative drug therapies to enter the Chinese market, the country’s National Healthcare Security Administration (NHSA) announced in August 2019 it will make 148 new drugs eligible for insurance reimbursement. Altogether, patients will be able to seek... Read More
Several years after it piloted a MAH system for medical devices in 4 locations in China, the government is expanding the pilot to 21 provinces/municipalities. The expanded Medical Device Marketing Authorization Holder (MAH) program will offer scientists and pharmaceutical research and development institutions... Read More
Determined to reduce prices of syringes, needles, sutures, staples, packaging, tubing, catheters, medical gloves, and other heavily used medical consumables, Chinese authorities in July unveiled a series of new cost-containment measures. The moves include a pilot program that would permit groups of... Read More
China’s Center for Medical Device Evaluation (CMDE) has expanded the number of medium and high-risk medical devices exempt from clinical requirements. The new list includes 142 more medical devices than were previously exempted. Manufacturers of Class II and Class III medical devices... Read More
Moving to centralize decision-making on drug reimbursement practices, China’s National Healthcare Security Administration has drafted a plan to decrease the ability of provincial governments to make adjustments to the prices of pharmaceuticals. The agency, which since its formation last November has played... Read More
Four years after China established a pilot program enabling drug license holders to use third parties to manufacture their products, the National Medical Products Administration in August launched a database to allow drug makers and the public to more easily access information... Read More